In antibody-drug conjugate (ADC) drug development, pharmacokinetic studies of anti-DXd/Exatecan payload antibodies are ongoing.

1. Accurate payload quantification:

   The presence of anti-DXD/Exatecan antibody hinders accurate determination of the amount of DXD bound to the antibody throughout the drug's life cycle in vivo and in the circulatory system. This measurement is critical to determine the capacity and efficacy of the administered drug and its impact on the user.

2. Stability assessment:

   Such rapid deconjugation rate can be used to understand the stability of DXD payload bound to antibody at different time scales. These data are critical for determining optimal formulation and storage conditions for ADC (antibody-drug conjugate).

3. Detailed Pharmacokinetics:

   When using anti-DXD/Exatecan antibodies for pharmacokinetic measurements, this method can distinguish the specific pharmacokinetic characteristics of the entire antibody-drug conjugate (ADC) as well as the free DXD payload. This distinction is crucial for considering the drug's action and metabolic pathways, including its distribution, metabolism, excretion, and potential toxic effects in the body.

4. Biodistribution studies:

   They are also used to evaluate the biodistribution of ADCs, i.e., the location of the drug and its payload in the body, thereby describing targeting effectiveness and potential damage to other organs.

1. Immunoassays:

   In pharmacokinetic studies, the two most commonly used techniques for quantifying or determining the binding affinity of anti-DXD/Exatecan antibodies are immunoassays, including ELISA. These assays can accurately and selectively identify and measure the concentration of DXD-conjugated antibodies in plasma or other biological fluids, thereby collecting useful information on ADC levels at different time points.

2. Immunohistochemistry:

   In tissue analysis, anti-DXD/Exatecan antibodies are very useful because they can identify the quantity and location of ADCs in tissues (mainly tumor cells). This helps evaluate the efficiency of ADCs in reaching the target tumor site and invading the surrounding microenvironment.

3. Mass spectrometry:

   Although anti-DXD/Exatecan antibodies cannot be directly used in mass spectrometry, they can be used in preparation steps, such as isolating and/or concentrating antibody-drug conjugates (ADCs) or free payloads from mixed biological matrices before mass spectrometry analysis. This can improve the signal-to-noise ratio and accuracy of mass spectrometry measurements.

4. Development and validation of detection methods:

   Anti-DXD/Exatecan antibodies play a crucial role in the creation and validation of sensitive, accurate, and reproducible detection methods for efficacy studies in preclinical and early clinical ADC development.

By using ligand charge conversion reagents (such as anti-DXD/Exatecan antibodies) in pharmacokinetic studies, researchers can understand the pharmacokinetics and pharmacodynamics of antibody-drug conjugates (ADCs), thereby optimizing their formulation, therapeutic dose, and side effects. DXD is one of the most promising platforms in ADC therapy; therefore, detailed evaluation of its effectiveness is essential to optimize the development of this therapeutic platform. This not only directly realizes its potential in delivering targeted drugs and minimizing side effects but also indirectly facilitates the approval of DXD derivatives by different regulatory agencies.